Basilea Pharmaceutica AG
BPMUF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $208,543 | $157,634 | $147,765 | $148,122 |
| % Growth | 32.3% | 6.7% | -0.2% | – |
| Cost of Goods Sold | $38,681 | $26,794 | $24,603 | $24,072 |
| Gross Profit | $169,862 | $130,840 | $123,162 | $124,050 |
| % Margin | 81.5% | 83% | 83.3% | 83.7% |
| R&D Expenses | $77,143 | $77,852 | $73,804 | $93,157 |
| G&A Expenses | $31,542 | $33,783 | $30,815 | $29,721 |
| SG&A Expenses | $31,542 | $33,783 | $30,815 | $29,721 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$73,804 | -$93,172 |
| Operating Expenses | $108,685 | $111,635 | $30,815 | $29,706 |
| Operating Income | $61,177 | $19,205 | $18,543 | $1,187 |
| % Margin | 29.3% | 12.2% | 12.5% | 0.8% |
| Other Income/Exp. Net | -$917 | -$8,744 | -$6,441 | -$7,981 |
| Pre-Tax Income | $60,260 | $10,461 | $12,102 | -$6,794 |
| Tax Expense | -$17,333 | $10 | -$45 | $37 |
| Net Income | $77,593 | $10,451 | $12,147 | -$6,831 |
| % Margin | 37.2% | 6.6% | 8.2% | -4.6% |
| EPS | 6.42 | 0.86 | 1.02 | -0.58 |
| % Growth | 646.5% | -15.7% | 275.9% | – |
| EPS Diluted | 5.83 | 0.86 | 1.02 | -0.58 |
| Weighted Avg Shares Out | 12,090 | 12,152 | 11,861 | 11,682 |
| Weighted Avg Shares Out Dil | 13,855 | 12,143 | 11,944 | 11,682 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,416 | $1,690 | $326 | $66 |
| Interest Expense | $4,344 | $11,202 | $9,848 | $8,151 |
| Depreciation & Amortization | $1,732 | $1,577 | $897 | $554 |
| EBITDA | $66,336 | $23,240 | $21,710 | $3,562 |
| % Margin | 31.8% | 14.7% | 14.7% | 2.4% |